This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

FPI-01

Formula Pharmaceuticals, Inc.

Drug Names(s): FPI-01, WT-1-vaccine

Description: FPI-01 is a unique, first-in-class, synthetic, multi-peptide immunotherapeutic that targets Wilm’s Tumor 1 (WT-1) antigen, a highly validated target for cancer immunotherapy. The lead indication for FPI-01 is acute myeloid leukemia (AML) in first-remission.

WT-1 is over-expressed (by up to 93% of patients) in many blood cancers and solid tumors, including AML, acute lymphocytic leukemia (ALL), mesothelioma, and cancers of the ovary, lung, breast and prostate. WT-1 was originally described as a tumor suppressor gene but it also appears to be involved in tumor formation and growth, as suggested by its up-regulation in these tumor types.

Deal Structure: Formula licensed FPI-01 on an exclusive worldwide basis from Memorial Sloan Kettering Cancer Center (MSKCC).


FPI-01 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug